Clinical trials: Brain Tumour
PCNSL, Brain Tumor
Neurocognitive Assessment CNSL and LGG
This study is to determine whether self-administered digital cognitive tests can serve as accurate and reliable alternatives to established neuropsychological tests for evaluating cognitive functioning in participants with…
- Conditions
- PCNSL, Brain Tumor, Cognitive Dysfunction, IDH Mutation
- Trial name
- NCT07710131
- Testing
- Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox), Traditional Neuropsychological Testing, Quality of Life and Mood Questionnaires
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
Adults Treated During Childhood or Adolescence for a Malignant Bone Tumor (Osteosarcoma and Ewing Sarcoma)
Long Term Brain Toxicity of Chemotherapy in Patients Treated for a Bone TumorDuring Childhood or Adolescence
To assess the neurocognitive outcomes in patients treated with chemotherapy for a malignant bone tumor during childhood and adolescence and the factors associated with neurocognitive impairment and/or complaints
- Trial name
- OSE (NCT05071001)
- Testing
- MRI
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Brain Neoplasms
Use of Fluorescein Dye for the Removal of Brain Tumors
Fluorescein is a dye agent that can be injected through an intravenous line. It has been shown to help tell the difference between brain tumor tissue and normal brain tissue when it is used together with a specialized filter on a…
- Trial name
- NCT02389530
- Testing
- Fluorescein
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- University of Pittsburgh
Brain Tumor, Cerebrovascular Disorders
The Neuroprotective Effects of Dexmedetomidine During Brain Surgery
Dexmedetomidine (DEX) is a Alpha-2 specific agonist, is a common ICU sedation medication. In brain tumor resection craniotomy, it is proven to be effective in improving postoperative hypertension and tachycardia, mitigates…
- Trial name
- NCT02878707
- Testing
- Dexmedetomidine
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- National Taiwan University Hospital
Posterior Fossa Tumor
Dexmedetomidine Use for Greater Occipital Nerve Block in Pediatric Posterior Fossa Tumor Surgery.
The goal of this clinical trial is to evaluate the effects of ultrasound-guided versus blind greater occipital nerve block (GONB), with or without Dexmedetomidine as an adjuvant, in pediatric patients undergoing posterior fossa…
- Trial name
- NCT07878156
- Testing
- Bupivacaine 0.25%, Dexmedetomidine 1mcg/kg, Blind greater occipital nerve block
- Where
- Egypt
- Volunteers
- 260 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Traumatic Brain Injury
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
The global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure…
- Trial name
- NCT05951777
- Testing
- Autologous HB-adMSCs, Normal Saline
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Hope Biosciences LLC
Recurrent Glioblastoma
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM), isocitrate dehydrogenase (IDH)-wildtype consistent with WHO central nervous…
- Trial name
- NCT07297212
- Testing
- Pumitamig, Bevacizumab, Temozolomide
- Where
- 6 sites in China
- Volunteers
- 75 people
- Sponsor
- BioNTech SE
Glioma, Primary Brain Tumor
MRI-based Computer Aided Diagnosis Software (V1) for Glioma
The goal of this multi-center clinical trial is to evaluate the effectiveness of MRI-based computer-aided diagnosis software (V1) for glioma segmentation, gene prediction, and tumor grading.
- Trial name
- NCT05739500
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Mingge LLC
Central Nervous System Neoplasm, Pineoblastoma
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
This randomized phase II trial studies how well giving temozolomide and irinotecan hydrochloride together with or without bevacizumab works in treating young patients with recurrent or refractory medulloblastoma or central…
- Conditions
- Central Nervous System Neoplasm, Pineoblastoma, Recurrent Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor
- Trial name
- NCT01217437
- Testing
- Bevacizumab, Irinotecan Hydrochloride, Temozolomide
- Where
- 158 sites in United States, Australia and 3 more
- Volunteers
- 108 people
- Sponsor
- National Cancer Institute (NCI)
Frozen Sections, Indocyanine Green (ICG)
A PROSPECTIVE, SINGLE-CENTERED, ASSESSOR-BLINDED STUDY TO EVALUATE THE CLINICAL EFFICACY OF THE PROPOSED CELL/TISSUE HISTOPATHOLOGY PROCESSOR CCELL (CONFOCAL FLUORESCENCE ENDOMICROSCOPY) FOR INTRAOPERATIVE DIAGNOSIS IN BRAIN TUMORS
The primary objective of this single-center study is to demonstrate the performance of cCeLL, used in real time, compared to frozen section analysis.
- Conditions
- Frozen Sections, Indocyanine Green (ICG), Brain Tumor
- Trial name
- NCT07254845
- Testing
- cCeLL In vivo, Indocyanine Green
- Volunteers
- 30 people
- Sponsor
- VPIX Medical
Brain Tumors, Non-CNS Malignancies
Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
In recent years, remarkable advances in medical oncology, surgery, and radiology have allowed for increasing cure rates for childhood malignancies.
- Trial name
- NCT01115777
- Testing
- Quality of Life surveys completed at specified timepoints
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Massachusetts General Hospital
Brain Metastases, Lung Cancer Metastatic
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
The study will use an Ommaya reservoir that drains into brain metastases to deliver activated, autolous dendritic cells to the tumor lesion, for patients who are 18 - 75 years old who have brain metastases from either lung cancer…
- Conditions
- Brain Metastases, Lung Cancer Metastatic, Breast Cancer Metastatic
- Trial name
- NCT03638765
- Testing
- DCVax-Direct
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northwest Biotherapeutics
Brain Tumor
Development and Validation of Advanced MRI Methods for Clinical Applications
A critical aspect of brain tumor patient management is the radiographic assessment of tumor status, which is used for diagnosis, localization, surgical planning and surveillance.
- Trial name
- NCT03264300
- Testing
- MRI
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Brain Metastasis
Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery
The goal of this protocol is to evaluate the potential of PET imaging of amino acid transport and microglial activation to improve the differentiation of tumor recurrence and radiation necrosis in patients with brain metastases…
- Trial name
- NCT02433171
- Testing
- Standard of Care FDG-PET Imaging
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Yale University
Primary Malignant Brain Tumors
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma
Glioma is a major histological subtype of primary malignant brain tumors in Taiwan, with distinct epidemiological, clinical, and pathological features comparing to the other common cancer diseases.
- Trial name
- NCT05622409
- Where
- 8 sites in Taiwan
- Volunteers
- 250 people
- Sponsor
- National Health Research Institutes, Taiwan
Recurrent Glioblastoma Multiforme
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody.
- Trial name
- NCT00509301
- Testing
- 131-I-chTNT-1/B MAB
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Peregrine Pharmaceuticals
Glioblastoma Multiforme, Glioblastoma
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma
- Trial name
- IMPACT (NCT05353530)
- Testing
- Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Florida
Tumors of the Central Nervous System, Childhood Cancer Survivors
Cardiovascular Disorders and Risk Factors in Childhood Cranial and Craniospinal Tumors Survivors
The purpose of research is to study to adverse cardiovascular disorder and risks factors in childhood cranial and craniospinal tumors survivors.
- Trial name
- NCT05641636
- Testing
- 12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis
- Where
- Russia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Glioblastoma, Glioblastoma Multiforme
The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.
The trial is designed as a multicenter randomized controlled study. 246 patients with presumed Glioblastoma Multiforme in eloquent areas on diagnostic MRI will be selected by the neurosurgeons according the eligibility criteria…
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Astrocytoma, Grade IV
- Trial name
- SAFE (NCT03861299)
- Testing
- Awake craniotomy, Craniotomy under general anesthesia
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 246 people
- Sponsor
- Jasper Gerritsen
DIPG Brain Tumor, Diffuse Intrinsic Pontine Glioma
Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.
- Trial name
- CMD03DIPG (NCT06221553)
- Testing
- B7H3 specific CAR T cell with IL-7Ra signaling domain
- Where
- Thailand
- Volunteers
- 9 people
- Sponsor
- Chulalongkorn University